« Return to News | Clinical Intelligence

Pinpoint Genomics publishes Dx Lung assay data

Tuesday, January 31, 2012 09:38 AM

Pinpoint Genomics has published key data relating to its Pinpoint Dx Lung assay in the journal The Lancet, and has made the assay available to clinicians and patients exclusively through the company's laboratory in Mountain View, Calif.

The Pinpoint Dx Lung assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell lung cancer, the most common form of lung cancer, in patients with early-stage disease.

The report in The Lancet describes the development of the assay based on specimens from 361 patients who underwent surgery at the University of California, San Francisco (UCSF). The assay was also based on results from the two largest independent, blinded studies to evaluate the clinical validity of a multi-gene molecular diagnostic assay for early-stage lung cancer, conducted by the Kaiser Permanente division of research—involving 433 patients—and the China Clinical Trials Consortium—a total of 1,006 patients from several leading cancer centers in China.

The Pinpoint Dx Lung assay is run on surgical specimens that undergo routine handling by pathology laboratories, making it immediately available to virtually all patients, and is offered through Pinpoint's Clinical Laboratory Improvement Amendment-certified laboratory.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.